This New Treatment Approach Could Be A Major Boost For Cystic Fibrosis Patients

According to a story from BioPortfolio, the pharmaceutical company Synspira announced the results of a study for poly-N glucosamine (PAAG) as a potential treatment for MRSA, a widespread antibiotic resistant infection. It can easily spread and is resistant to multiple forms of treatment. It affects 2 million people across the US each year. MRSA is also becoming increasing more common in patients with cystic fibrosis, and is responsible for declines in lung function.

In cystic fibrosis, patients are born with a genetic mutation that leaves the body vulnerable to infection, especially in the lungs. Due to the frequent infections, cystic fibrosis patients often have to take antibiotics for much of their lives. To learn more about cystic fibrosis, click here.

Later in life, the heavy use of antibiotics causes bacteria in the lungs to transition to more antibiotic resistant strains, which makes treatment progressively more difficult. As antibiotic therapy decreases in effectiveness, patients may have to undergo a lung transplant if they are to survive. Therefore, antibiotic resistant infections like MRSA can be a serious challenge for someone with CF.

PAAG functions by mimicking and enhancing the body’s immune system. PAAG and glycopolymers will not replace the use of antibiotics, but are intended to be used in combination with them. In the study, PAAG was able to significantly improve the effectiveness of antibiotic treatment, and the dosage needed to kill bacteria was substantially lower. In effect, PAAG serves to make bacteria that were previously resistant to antibiotics vulnerable again.

The drug has entered Phase I clinical trials for the treatment of cystic fibrosis. Although the drug was only tested against MRSA during the study, researchers believe that the mechanism of action should work for other multidrug resistant bacterial infections as well. Other studies have shown similar effectiveness of PAAG against other species of resistant bacteria. PAAG is the active component in SNSP113, the product being developed by Synspira for treating CF. SNSP113 is an inhaled treatment that will work by breaking down the biofilms that protect bacteria and will also reduce the amount of thick, sticky mucus that it present in CF. This mucus also provides habitat for the dangerous bacteria that can cause infection.

Share this post

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.
Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

© Copyright Patient Worthy

Close Menu